Nothing Special   »   [go: up one dir, main page]

MX2020001877A - Formulaciones farmacéuticas para tratar la endometriosis, los fibromas uterinos, el síndrome de ovario poliquístico o la adenomiosis. - Google Patents

Formulaciones farmacéuticas para tratar la endometriosis, los fibromas uterinos, el síndrome de ovario poliquístico o la adenomiosis.

Info

Publication number
MX2020001877A
MX2020001877A MX2020001877A MX2020001877A MX2020001877A MX 2020001877 A MX2020001877 A MX 2020001877A MX 2020001877 A MX2020001877 A MX 2020001877A MX 2020001877 A MX2020001877 A MX 2020001877A MX 2020001877 A MX2020001877 A MX 2020001877A
Authority
MX
Mexico
Prior art keywords
adenomyosis
pharmaceutical formulations
polycystic ovary
ovary syndrome
uterine fibroids
Prior art date
Application number
MX2020001877A
Other languages
English (en)
Inventor
Jayanthy Jayanth
Kevin C Spence
Gregory A Mcclelland
Anna V Stepanenko
Kristof Chwalisz
Charolotte D Owens
James W Thomas
Jane Castelli-Haley
Keith Gordon
Michael C Snabes
Ahmed M Soliman
Geoff Zhang
David Metzger
Yanxia Li
Tzuchi R Ju
Xi Shao
Oscar Antunez Flores
Rita Jain
Wing - Keung Juki NG
Janine D North
Hannah Palac
Paul M Peloso
Original Assignee
Abbvie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2018/043321 external-priority patent/WO2019203870A1/en
Application filed by Abbvie Inc filed Critical Abbvie Inc
Priority claimed from PCT/US2018/047072 external-priority patent/WO2019036712A1/en
Publication of MX2020001877A publication Critical patent/MX2020001877A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5015—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Reproductive Health (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente divulgación se refiere a composiciones farmacéuticas que comprenden un antagonista de la hormona liberadora de gonadotropina (GnRH) y a métodos para preparar y usar tales composiciones. La divulgación también se refiere a métodos para facilitar la liberación de un antagonista de GnRH desde una composición farmacéutica.
MX2020001877A 2017-08-18 2018-08-20 Formulaciones farmacéuticas para tratar la endometriosis, los fibromas uterinos, el síndrome de ovario poliquístico o la adenomiosis. MX2020001877A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762547402P 2017-08-18 2017-08-18
US201862660102P 2018-04-19 2018-04-19
PCT/US2018/043321 WO2019203870A1 (en) 2018-04-19 2018-07-23 Methods of treating heavy menstrual bleeding
PCT/US2018/047072 WO2019036712A1 (en) 2017-08-18 2018-08-20 PHARMACEUTICAL FORMULATIONS FOR THE TREATMENT OF ENDOMETRIOSIS, UTERINE FIBROIDS, POLYKYSTIC OVARY SYNDROME OR ADENOMYOSIS

Publications (1)

Publication Number Publication Date
MX2020001877A true MX2020001877A (es) 2020-09-14

Family

ID=69636711

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2020001877A MX2020001877A (es) 2017-08-18 2018-08-20 Formulaciones farmacéuticas para tratar la endometriosis, los fibromas uterinos, el síndrome de ovario poliquístico o la adenomiosis.
MX2023002450A MX2023002450A (es) 2017-08-18 2020-02-17 Formulaciones farmaceuticas para tratar la endometriosis, los fibromas uterinos, el sindrome de ovario poliquistico o la adenomiosis.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2023002450A MX2023002450A (es) 2017-08-18 2020-02-17 Formulaciones farmaceuticas para tratar la endometriosis, los fibromas uterinos, el sindrome de ovario poliquistico o la adenomiosis.

Country Status (12)

Country Link
US (1) US12102637B2 (es)
EP (1) EP3668515A4 (es)
JP (2) JP7374885B2 (es)
KR (1) KR20200109291A (es)
CN (1) CN111698992A (es)
AU (1) AU2018317472A1 (es)
BR (1) BR112020003380A2 (es)
CA (1) CA3073229A1 (es)
EA (1) EA202090461A1 (es)
IL (1) IL272723A (es)
MX (2) MX2020001877A (es)
SG (1) SG11202001436YA (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112494425B (zh) * 2020-12-14 2023-06-23 珠海优润医药科技有限公司 一种恶拉戈利钠口服溶液及其制备方法
WO2022222886A1 (zh) * 2021-04-21 2022-10-27 上海启晟合研医药科技有限公司 一种噁拉戈利钠组合物
JPWO2023074785A1 (es) * 2021-10-28 2023-05-04
CN113876728B (zh) * 2021-11-17 2022-12-13 南京唯创远医药科技有限公司 一种噁拉戈利冻干片及其制备方法
CN114948889A (zh) * 2022-06-17 2022-08-30 哈药集团技术中心 一种噁拉戈利片的制备方法及其制备的噁拉戈利片
CN115804774B (zh) * 2022-08-26 2024-08-20 济川(上海)医学科技有限公司 一种噁拉戈利的药物组合物，包含其的药物制剂，及其应用
CN116459225B (zh) * 2023-04-26 2023-11-10 东莞市金美济药业有限公司 一种艾拉戈克钠片及其制备工艺

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4311606A (en) 1980-03-10 1982-01-19 Colgate Palmolive Company Method for manufacture of non-gelling, stable inorganic salt crutcher slurries
US4800035A (en) * 1984-04-06 1989-01-24 Colgate-Palmolive Company Liquid laundry detergent composition containing polyphosphate
US5433959A (en) 1986-02-13 1995-07-18 Takeda Chemical Industries, Ltd. Stabilized pharmaceutical composition
DE3928183A1 (de) 1989-08-25 1991-02-28 Goedecke Ag Lactamfreie cyclische aminosaeuren
DE69905452D1 (de) 1998-03-03 2003-03-27 Daewoong Pharmaceutical Co Feuchtigkeitsstabile cefuroxim axetil enthaltende pharmazeutische zusammenstellungen
ES2202069T3 (es) * 1999-03-19 2004-04-01 Ranbaxy Laboratories, Ltd. Procedimiento para la preparacion de una forma de dosificacion oral biodisponible de axetil cefuroxima.
US20020065309A1 (en) 1999-08-04 2002-05-30 Ge Peng Novel Bicyclic and tricyclic pyrrolidine derivatives as GnRH antagonists
CA2383510A1 (en) 1999-09-23 2001-03-29 Zentaris Ag Method for the therapeutic management of extrauterine proliferation of endometreial tissue, chronic pelvic pain and fallopian tube obstruction
US6544553B1 (en) 1999-12-28 2003-04-08 Watson Pharmaceuticals, Inc. Dosage forms and methods for oral delivery of progesterone
ATE548357T1 (de) 2000-01-25 2012-03-15 Neurocrine Biosciences Inc Gonadotropin freisetzende hormon rezeptor antagonisten und ihre verwandten verfahren
JP2002326960A (ja) 2000-12-15 2002-11-15 Takeda Chem Ind Ltd 組成物、その製造法および用途
JPWO2002061931A1 (ja) 2001-01-30 2004-06-03 株式会社ルネサステクノロジ 昇圧型電源回路および液晶表示装置並びに携帯用電子機器
US20060057207A1 (en) 2001-11-30 2006-03-16 Pfizer Inc Fast-disintegrating dosage forms of 5,8,14-triazatetracyclo[10.3.1.02,11.04,9]-hexadeca-2(11),3,5,7,9-pentaene
WO2003101431A1 (en) * 2002-06-04 2003-12-11 J.B. Chemicals & Pharmaceuticals Ltd. Pharmaceutical composition for controlled drug delivery system
CA2395931A1 (en) 2002-08-07 2004-02-07 Bernard Charles Sherman Solid compositions comprising gabapentin having improved stability
CN1720025A (zh) 2002-10-08 2006-01-11 兰贝克赛实验室有限公司 加巴喷丁片剂及其制备
US20050271717A1 (en) 2003-06-12 2005-12-08 Alfred Berchielli Pharmaceutical compositions of atorvastatin
CN100424078C (zh) 2003-07-07 2008-10-08 纽罗克里生物科学有限公司 作为促性激素释放激素受体拮抗剂的嘧啶-2,4-二酮衍生物
WO2005020978A1 (en) 2003-09-03 2005-03-10 Ranbaxy Laboratories Limited Sustained release oral tablets of gabapentin and process for their preparation
CN1921839A (zh) 2004-01-19 2007-02-28 兰贝克赛实验室有限公司 加巴喷丁的稳定缓释口服剂型及其制备方法
WO2006030826A1 (ja) 2004-09-17 2006-03-23 Eisai R & D Management Co., Ltd. 医薬組成物
CN101693029B (zh) 2004-11-23 2011-11-02 同和药品（株） 具有改善生物利用度的口服制剂
WO2007107835A2 (en) 2006-03-17 2007-09-27 Aurobindo Pharma Limited Stable liquid formulations of antiepileptic agents
ES2288117B1 (es) 2006-05-08 2008-12-01 Combino Pharm, S.L. Composicion farmaceutica solida de gabapentina.
CN100572491C (zh) * 2007-10-10 2009-12-23 中国石油集团渤海钻探工程有限公司 油井注水泥前置液外加剂及制备方法
WO2009062087A1 (en) 2007-11-07 2009-05-14 Neurocrine Biosciences, Inc. Processes for the preparation of uracil derivatives
CN107096012A (zh) 2008-05-07 2017-08-29 诺和诺德股份有限公司 肽的组合物及其制备方法
US20120108464A1 (en) 2009-01-29 2012-05-03 Sanofi-Aventis Test systems, methods and uses involving as160 protein
CN102858740B (zh) 2010-04-19 2015-10-21 中化帝斯曼制药有限公司荷兰公司 低内酯杂质的阿托伐他汀的制备
AU2011295837B2 (en) 2010-09-03 2015-06-18 Astrazeneca Uk Limited Drug formulations using water soluble antioxidants
US20120165386A1 (en) 2010-12-27 2012-06-28 Ranbaxy Laboratories Limited Stable oral pharmaceutial composition of atorvastatin
ITFI20120128A1 (it) 2012-06-21 2013-12-22 Valpharma Internat Spa Formulazioni per la preparazione di compresse per uso orale a rilascio immediato contenenti mifepristone a basso dosaggio per il trattamento di endometriosi, compresse così ottenute e loro processo di preparazione.
US9138425B2 (en) * 2013-03-12 2015-09-22 Patheon Inc. Drug delivery system to increase bioavailability
CA2906894A1 (en) * 2013-03-15 2014-09-18 Abbvie Inc. Compositions comprising elagolix for use in treating pain associated with endometriosis
CA2910121A1 (en) * 2013-04-25 2014-10-30 Kyorin Pharmaceutical Co., Ltd. A pharmaceutical composition comprising a 1,4-dihydroquinoline carboxylic acid a cellulosic excipient and a salting-out agent
US20160008777A1 (en) 2014-07-09 2016-01-14 Novotec Consulting Inc. Pharmaceutical compounding kit
HRP20230613T1 (hr) 2015-02-26 2023-09-29 Takeda Pharmaceutical Company Limited Tableta koja sadrži derivat metoksiureje i čestice manitola
EP3302442B1 (en) * 2015-06-03 2024-10-16 Triastek, Inc. Dosage forms and use thereof
CN109432039B (zh) * 2015-06-03 2021-06-22 南京三迭纪医药科技有限公司 药品剂型及其使用
WO2017007895A1 (en) * 2015-07-07 2017-01-12 Abbvie Inc. Acoustic mixing for auto granulation
JP6471975B2 (ja) 2015-07-31 2019-02-20 パナソニックＩｐマネジメント株式会社 三次元形状造形物の製造方法および三次元形状造形物
CA3002791A1 (en) 2015-09-01 2017-03-09 Abbvie Inc. Methods of administering elagolix
WO2017221144A1 (en) 2016-06-20 2017-12-28 Dr. Reddy's Laboratories Limited Process for the preparation of elagolix sodium and its polymorph
CN106619547A (zh) * 2016-11-18 2017-05-10 江苏飞马药业有限公司 一种低规格美洛昔康片剂组合物及其制备方法
WO2018189212A1 (en) 2017-04-12 2018-10-18 Sandoz Ag Acid addition salts of an orally available gonadotropin-releasing hormone receptor antagonist
ES2770132T3 (es) * 2017-04-13 2020-06-30 Sandoz Ag Dispersión sólida amorfa de un antagonista del receptor de la hormona liberadora de gonadotropina disponible por vía oral
WO2018198086A1 (en) 2017-04-28 2018-11-01 Lupin Limited Process for the preparation of elagolix and pharmaceutically acceptable salts thereof
WO2018224063A2 (en) 2017-06-08 2018-12-13 Zentiva, K.S. Solid forms of elagolix
TW201912157A (zh) 2017-08-18 2019-04-01 美商艾伯維有限公司 治療子宮內膜異位症、子宮纖維瘤、多囊性卵巢症候群及子宮腺肌症之固體醫藥調配物
CN108129400B (zh) 2017-12-29 2021-10-15 安帝康（无锡）生物科技有限公司 氘代噁拉戈利衍生物及其用途
CN108586359B (zh) 2018-06-26 2020-04-28 杭州科巢生物科技有限公司 一种恶拉戈利的合成方法
WO2020020999A1 (en) 2018-07-27 2020-01-30 Sandoz Ag Process for preparing rapidly or very rapidly dissolving tablets comprising freely soluble api
WO2020043763A1 (en) 2018-08-31 2020-03-05 Sandoz Ag Process for preparing elagolix formulations and dosage forms comprising the same

Also Published As

Publication number Publication date
JP7374885B2 (ja) 2023-11-07
CA3073229A1 (en) 2019-02-21
JP2023153796A (ja) 2023-10-18
CN111698992A (zh) 2020-09-22
EA202090461A1 (ru) 2020-06-29
JP2020531477A (ja) 2020-11-05
US12102637B2 (en) 2024-10-01
KR20200109291A (ko) 2020-09-22
EP3668515A4 (en) 2021-05-12
EP3668515A1 (en) 2020-06-24
AU2018317472A1 (en) 2020-03-05
MX2023002450A (es) 2023-03-23
IL272723A (en) 2020-04-30
SG11202001436YA (en) 2020-03-30
BR112020003380A2 (pt) 2020-08-25
US20230255968A1 (en) 2023-08-17

Similar Documents

Publication Publication Date Title
MX2023002450A (es) Formulaciones farmaceuticas para tratar la endometriosis, los fibromas uterinos, el sindrome de ovario poliquistico o la adenomiosis.
MX2023002449A (es) Formulaciones farmaceuticas solidas para tratar la endometriosis, los fibromas uterinos, el sindrome de ovario poliquistico y la adenomiosis.
MX2022003967A (es) Composiciones y metodos para la liberacion prolongada de antagonistas de la hormona liberadora de gonadotropina (gnrh).
MX2020005462A (es) Compuestos de indol sustituidos utiles como inhibidores de receptores tipo toll (tlr).
MX2018006217A (es) Agonistas del receptor de apelina y metodos de uso.
MX2020005513A (es) Compuestos de amino indol utiles como inhibidores de receptores tipo toll (tlr).
MX2020005622A (es) Compuestos de indol sustituidos con arilo y heteroarilo.
MX2020005873A (es) Compuestos de 6-azaindol.
MX2018007319A (es) Imidazoquinolinas pegiladas como agonistas tlr7 y tlr8.
MY189454A (en) 6-hydroxy-4-oxo-1,4-dihydropyrimidine-5-carboxamides as apj agonists
MX2018007155A (es) Heteroarilhidroxipirimidinonas como agonistas del receptor de apelina (apj).
MX2020006014A (es) Compuestos de diazaindol.
MX2018004344A (es) 2,4-dihidroxi-nicotinamidas como agonistas del recepor de apelina (apj).
ZA202002852B (en) Stable vaccine compositions comprising inter alia live attenuated recombinant flavivirus and process for preparation thereof
PH12019500731A1 (en) Novel monocyclic and bicyclic ring system substituted carbanucleoside analogues for use as prmt5 inhibitors
NZ763528A (en) Heterocyclic gpr119 agonist compounds
MX2020006093A (es) Compuestos de indol eter sustituidos.
EP3450449A3 (en) Peptide compositions
WO2016038521A8 (en) Pharmaceutical compositions of liraglutide
PH12019500567A1 (en) Crystalline forms
MX2018005134A (es) Formulacion de factor viii (fviii).
MX2019003815A (es) Composiciones farmaceuticas de antagonista del 5-ht6.
MX2019009230A (es) Composicion que comprende capecitabina de liberacion inmediata y liberacion prolongada.
MX2018013274A (es) Uso de alcoholes de azucar en composiciones de tibolona.